--- title: "\"Active Stocks\" Pharmaron falls about 2% after a surge, collaborates with Eli Lilly on oral GLP weight loss medication" type: "News" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/278997262.md" description: "Pharmaron's stock price rose 13% yesterday, closing up 8%, and today it has retraced about 1.9%, currently reported at 19.77 yuan. The company has reached a production cooperation agreement with Eli Lilly for the oral GLP-1 receptor agonist Orforglipron. The current price of A shares is 27.84 yuan, down 1.9%, with a premium of 59.8% for A shares over H shares. Pharmaron stated that this cooperation is part of its regular business" datetime: "2026-03-13T07:01:00.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/278997262.md) - [en](https://longbridge.com/en/news/278997262.md) - [zh-HK](https://longbridge.com/zh-HK/news/278997262.md) --- > 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/278997262.md) | [English](https://longbridge.com/en/news/278997262.md) # "Active Stocks" Pharmaron falls about 2% after a surge, collaborates with Eli Lilly on oral GLP weight loss medication According to the Economic News Agency on the 13th, Pharmaron (03759) suddenly surged by 13% yesterday, closing up 8% for the day. Today, it has temporarily retraced by 1.9%, reporting at HKD 19.77, with a trading volume of approximately 6.41 million shares, involving HKD 127 million. The current price of A shares (Shenzhen: 300759) is RMB 27.84, down 1.9%, with a trading volume of RMB 698 million, involving 24.91 million shares. The current price of A shares is at a premium of 59.8% over H shares. Pharmaron announced that, at the request of the Hong Kong Stock Exchange, it is making an announcement regarding recent news reports about the group's production cooperation with a Chinese subsidiary of a leading international pharmaceutical company. After inquiries, it was confirmed that the production cooperation was established and will be conducted in the course of the group's routine and general business operations. In its daily operations, the group collaborates with various companies across different fields to advance its business development goals. Pharmaron's official Weibo announced that the company has reached a production cooperation agreement with Eli Lilly for the first reported registration of the oral small molecule GLP-1 receptor agonist Orforglipron. (am) ### 相關股票 - [Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF (159506.CN)](https://longbridge.com/zh-HK/quote/159506.CN.md) - [China Universal CNI HK Connect Innovative Drugs Industry ETF (159570.CN)](https://longbridge.com/zh-HK/quote/159570.CN.md) - [Penghua SSE STAR Biology and Medicine ETF (588250.CN)](https://longbridge.com/zh-HK/quote/588250.CN.md) - [Ping An CSI Medicine and Medical Device Innovation ETF (516820.CN)](https://longbridge.com/zh-HK/quote/516820.CN.md) - [ChinaAMC Hang Seng Biotechnology Technology ETF(QDII) (159892.CN)](https://longbridge.com/zh-HK/quote/159892.CN.md) - [Guotai CSI Bio-medicine ETF (512290.CN)](https://longbridge.com/zh-HK/quote/512290.CN.md) - [ChinaAMC SSE STAR Biology and Medicine ETF (588130.CN)](https://longbridge.com/zh-HK/quote/588130.CN.md) - [Founder Fubon CSI Medicine and Medical Device Innovation ETF (560600.CN)](https://longbridge.com/zh-HK/quote/560600.CN.md) - [E Fund CSI 300 Health Care ETF (512010.CN)](https://longbridge.com/zh-HK/quote/512010.CN.md) - [E Fund CSI Biotechnology Theme ETF (159837.CN)](https://longbridge.com/zh-HK/quote/159837.CN.md) - [ChinaAMC SSE Health Care ETF Initiating Fund (510660.CN)](https://longbridge.com/zh-HK/quote/510660.CN.md) - [Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII) (520500.CN)](https://longbridge.com/zh-HK/quote/520500.CN.md) - [Huaan Hang Seng Biotech ETF (159102.CN)](https://longbridge.com/zh-HK/quote/159102.CN.md) - [Minsheng Royal CSI Biotechnology Theme ETF (516930.CN)](https://longbridge.com/zh-HK/quote/516930.CN.md) - [ChinaAMC CSI Biotechnology Theme ETF (516500.CN)](https://longbridge.com/zh-HK/quote/516500.CN.md) - [Hwabao WP Hang Seng SCHK Innovative Drug Select ETF (520880.CN)](https://longbridge.com/zh-HK/quote/520880.CN.md) - [China Merchants CSI Biotechnology Theme ETF (159849.CN)](https://longbridge.com/zh-HK/quote/159849.CN.md) - [Hwabao WP CSI Pharmaceuticals ETF (562050.CN)](https://longbridge.com/zh-HK/quote/562050.CN.md) - [E Fund Hang Seng SCHK Innovative Drug ETF (159316.CN)](https://longbridge.com/zh-HK/quote/159316.CN.md) - [Bosera Hang Seng SCHK Innovative Drug Select ETF (520690.CN)](https://longbridge.com/zh-HK/quote/520690.CN.md) - [PHARMARON (03759.HK)](https://longbridge.com/zh-HK/quote/03759.HK.md) - [ICBCCS SSE STAR Biology and Medicine ETF (588860.CN)](https://longbridge.com/zh-HK/quote/588860.CN.md) - [Pharmaron (300759.CN)](https://longbridge.com/zh-HK/quote/300759.CN.md) - [Yinhua CSI Innovative Drugs Industry ETF (159992.CN)](https://longbridge.com/zh-HK/quote/159992.CN.md) - [Eli Lilly (LLY.US)](https://longbridge.com/zh-HK/quote/LLY.US.md) - [Tianhong CNI BIOMEDICINE ETF (159859.CN)](https://longbridge.com/zh-HK/quote/159859.CN.md) - [Penghua CSI HK Connect Health Care Composite ETF (513700.CN)](https://longbridge.com/zh-HK/quote/513700.CN.md) - [GF CSI HK Innovative Drugs Industry ETF(QDII) (513120.CN)](https://longbridge.com/zh-HK/quote/513120.CN.md) ## 相關資訊與研究 - [SSY Group Wins China Approval for Upadacitinib Bulk Drug](https://longbridge.com/zh-HK/news/281103720.md) - [Clover Biopharmaceuticals Completes Enrollment in Phase 2 Trial for Combination Respiratory Vaccines](https://longbridge.com/zh-HK/news/280923090.md) - [FDA approves Eli Lilly's GLP-1 pill, opening the next phase of the weight loss drug market](https://longbridge.com/zh-HK/news/281394441.md) - [Eli Lilly Stock (LLY) Surges as FDA Approves Weight-Loss Pill](https://longbridge.com/zh-HK/news/281437997.md) - [Eli Lilly: Foundayo will be available with prescriptions accepted immediately and shipping from April 6](https://longbridge.com/zh-HK/news/281395595.md)